Predictors of Severe COVID-19 Outcomes (PRESCO)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Respiratory Distress Syndrome
- Sponsor
- Verily Life Sciences LLC
- Enrollment
- 494
- Locations
- 8
- Primary Endpoint
- Performance (discrimination / calibration) of models
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant or legally authorized representative willing and able to provide informed consent
- •Receiving care at a participating site
- •Age 18 years old or older
- •U.S. Resident
- •Confirmed positive for COVID-19
- •Willing and able to comply with all study procedures
Exclusion Criteria
- •Self reported pregnancy
Outcomes
Primary Outcomes
Performance (discrimination / calibration) of models
Time Frame: From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months).
Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.